RT Journal Article
SR Electronic
T1 The genomic landscape across 474 surgically accessible epileptogenic human brain lesions
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.14.22271705
DO 10.1101/2022.03.14.22271705
A1 López-Rivera, Javier A.
A1 Leu, Costin
A1 Macnee, Marie
A1 Khoury, Jean
A1 Hoffmann, Lucas
A1 Coras, Roland
A1 Kobow, Katja
A1 Bhattarai, Nisha
A1 Pérez-Palma, Eduardo
A1 Hamer, Hajo
A1 Brandner, Sebastian
A1 Rössler, Karl
A1 Bien, Christian G.
A1 Kalbhenn, Thilo
A1 Pieper, Tom
A1 Hartlieb, Till
A1 Butler, Elizabeth
A1 Genovese, Giulio
A1 Becker, Kerstin
A1 Altmüller, Janine
A1 Niestroj, Lisa-Marie
A1 Ferguson, Lisa
A1 Busch, Robyn M.
A1 Nürnberg, Peter
A1 Najm, Imad
A1 Blümcke, Ingmar
A1 Lal, Dennis
YR 2022
UL http://medrxiv.org/content/early/2022/03/15/2022.03.14.22271705.abstract
AB Understanding the exact molecular mechanisms involved in the etiology of epileptogenic pathologies with or without tumor activity is essential for improving treatment of drug-resistant focal epilepsy. Here, we characterize the landscape of somatic genetic variants in resected brain specimens from 474 individuals with drug-resistant focal epilepsy using deep whole-exome sequencing (>350×) and whole-genome genotyping. Across the exome, we observe a greater number of somatic single-nucleotide variants (SNV) in low-grade epilepsy-associated tumors (LEAT; 7.92±5.65 SNV) than in brain tissue from malformations of cortical development (MCD; 6.11±4 SNV) or hippocampal sclerosis (HS; 5.1±3.04 SNV). Tumor tissues also had the largest number of likely pathogenic variant carrying cells. LEAT had the highest proportion of samples with one or more somatic copy number variants (CNV; 24.7%), followed by MCD (5.4%) and HS (4.1%). Recurring somatic whole chromosome duplications affecting Chromosome 7 (16.8%), chromosome 5 (10.9%), and chromosome 20 (9.9%) were observed among LEAT. For germline variant-associated MCD genes such as TSC2, DEPDC5, and PTEN, germline SNV were frequently identified within large loss of heterozygosity regions, supporting the recently proposed ‘second hit’ disease mechanism in these genes. We detect somatic variants in twelve established lesional epilepsy genes and demonstrate exome-wide statistical support for three of these in the etiology of LEAT (e.g., BRAF) and MCD (e.g., SLC35A2 and MTOR). We also identify novel significant associations for PTPN11 with LEAT and NRAS Q61 mutated protein with a complex MCD characterized by polymicrogyria and nodular heterotopia. The variants identified in NRAS are known from cancer studies to lead to hyperactivation of NRAS, which can be targeted pharmacologically. We identify large recurrent 1q21-q44 duplication including AKT3 in association with focal cortical dysplasia type 2a with hyaline astrocytic inclusions, another rare and possibly under-recognized brain lesion. The clinical genetic analyses showed that the numbers of somatic SNV across the exome and the fraction of affected cells were positively correlated with the age at seizure onset and surgery in individuals with LEAT. Finally, we report that identifying a likely pathogenic variant enabled us to refine or reclassify previous histopathological classifications post hoc in 20.5% of diagnoses. In summary, our comprehensive genetic screen sheds light on the genome-scale landscape of genetic variants in epileptic brain lesions, informs the design of gene panels for clinical diagnostic screening, and guides future directions for clinical implementation of epilepsy surgery genetics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by research funding from the German Research Council (DFG, grant agreement numbers BL 421/4-1 and NU 50/13-1). Sequencing was facilitated by the DFG-funded West German Genome Center (WGGC).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All studies were performed following institutional guidelines and regulations regarding research involving human subjects and approved by the ethics review boards of the Cleveland Clinic and the University of Erlangen, Germany. Brain tissue samples and clinical data were obtained from existing IRB-approved biobanks and data registries.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsDNETDysembryoplastic neuroepithelial tumorCNN-LOHCopy number neutral loss of heterozygosityCNVCopy number variantFCDFocal cortical dysplasiaGGGangliogliomaHMEHemimegalencephalyHSHippocampal sclerosisLEATLow-grade epilepsy-associated tumorMCDMalformation of cortical developmentmMCDmild MCDMOGHEmMCD with oligodendroglial hyperplasia in epilepsyNHNodular heterotopiaPMGPolymicrogyriaPTVProtein-truncating variantSNVSingle nucleotide variantVAFVariant allele fractionWESWhole exome sequencing